Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation A Prospective Nationwide Cohort Study
ConclusionsIn this “everyday clinical practice” post-approval nationwide clinical cohort, there were similar stroke/systemic embolism and major bleeding rates with dabigatran (both doses) compared with warfarin. Mortality, intracranial bleeding, pulmonary embolism, and MI were lower with dabigatran, compared with warfarin. We found no evidence of an excess of bleeding events or MI among dabigatran-treated patients in this propensity-matched comparison against warfarin, even in the subgroup with ≥1-year follow-up.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Coumadin | Gastroenterology | Heart | Heart Attack | Pradaxa | Pulmonary Thromboembolism | Statistics | Stroke | Study | Warfarin